Suppr超能文献

回顾性分析评估胃癌根治术后辅助化疗最佳间隔时间的真实世界数据。

Retrospective Analysis of Real-Life Data Evaluating the Optimal Time Between Gastrectomy and Adjuvant Chemotherapy in Resected Gastric Cancer.

机构信息

Department of Medical Oncology, Gazi University, Ankara, Turkey.

出版信息

J Gastrointest Cancer. 2023 Dec;54(4):1268-1275. doi: 10.1007/s12029-023-00916-5. Epub 2023 Feb 23.

Abstract

PURPOSE

Although adjuvant chemotherapy (AC) increases survival in early-stage gastric cancer, the effect of the time between gastrectomy and the initiation of AC on survival has not been clearly demonstrated. This study aimed to examine the effect of AC timing on survival.

METHODS

The data of patients who received AC in the postoperative period with the diagnosis of stage II and stage III gastric cancer were analyzed retrospectively. The patients were separated into two groups based on a 4-week cut-off value between the date of gastrectomy and the initiation of AC.

RESULTS

There were 151 patients enrolled in the study. It was determined that 63 (41.7%) patients started AC in the first 4 weeks and 88 (58.3%) patients after the first 4 weeks. Patients who received AC during the first 4 weeks had a median recurrence-free survival (RFS) of 46 months, while those who received AC after 4 weeks had a median RFS of 29 months (p = 0.039). The median overall survival (OS) for patients administered AC in the first 4 weeks was 65 months, compared to 45 months for those administered AC after 4 weeks (p = 0.036). The early time interval from surgery to AC resulted as an independent prognostic factor for both OS and RFS.

CONCLUSION

The optimal time to start AC in patients with gastric cancer who underwent curative resection is unknown. This study reported that an interval shorter than 4 weeks was an independent prognostic risk factor for both OS and RFS.

摘要

目的

尽管辅助化疗(AC)可提高早期胃癌患者的生存率,但胃切除术后与开始 AC 之间的时间对生存的影响尚未明确。本研究旨在探讨 AC 时机对生存的影响。

方法

回顾性分析接受术后 AC 治疗、诊断为 II 期和 III 期胃癌患者的数据。根据胃切除术与 AC 开始日期之间的 4 周截止值,将患者分为两组。

结果

本研究纳入了 151 例患者。结果确定,63 例(41.7%)患者在第 1 至 4 周内开始接受 AC,88 例(58.3%)患者在第 4 周后开始接受 AC。在第 1 至 4 周内接受 AC 的患者中位无复发生存期(RFS)为 46 个月,而在第 4 周后接受 AC 的患者中位 RFS 为 29 个月(p=0.039)。在第 1 至 4 周内接受 AC 的患者中位总生存期(OS)为 65 个月,而在第 4 周后接受 AC 的患者中位 OS 为 45 个月(p=0.036)。从手术到 AC 的早期时间间隔是 OS 和 RFS 的独立预后因素。

结论

接受根治性切除术的胃癌患者开始 AC 的最佳时间尚不清楚。本研究报告称,间隔时间短于 4 周是 OS 和 RFS 的独立预后危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验